SINOMAB BIOSCIENCE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.84 HKD | -0.54% |
|
-2.13% | +9.52% |
| 03-25 | SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-07 | SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,183 | 3,896 | 2,345 | 1,654 | 1,580 |
| Enterprise Value (EV) 1 | 2,030 | 3,077 | 2,031 | 1,589 | 1,794 |
| P/E ratio | -9.58 x | -31.8 x | -8.04 x | -5.58 x | -6.39 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 305,310,671 x | 87,965,706 x | 410,312,471 x | 359,810,493 x |
| EV / Revenue | - | 241,175,561 x | 76,183,773 x | 394,141,340 x | 408,371,513 x |
| EV / EBITDA | -8.76 x | -19.4 x | -6.85 x | -6.51 x | -8.52 x |
| EV / FCF | -24.2 x | -14.4 x | -7.44 x | -7.6 x | -7.33 x |
| FCF Yield | -4.14% | -6.96% | -13.4% | -13.2% | -13.6% |
| Price to Book | 2.81 x | 3.95 x | 3.45 x | 3.25 x | 5.35 x |
| Nbr of stocks (in thousands) | 1,006,240 | 1,006,240 | 1,006,240 | 1,034,920 | 1,034,920 |
| Reference price 2 | 3.164 | 3.872 | 2.330 | 1.599 | 1.527 |
| Announcement Date | 27/04/20 | 28/04/21 | 27/04/22 | 26/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 12.76 | 26.66 | 4.032 | 4.392 |
| EBITDA 1 | -55.2 | -231.8 | -158.6 | -296.4 | -244.3 | -210.4 |
| EBIT 1 | -56.28 | -234 | -162.7 | -305.9 | -258.9 | -229.6 |
| Operating Margin | - | - | -1,274.7% | -1,147.38% | -6,421.8% | -5,227.12% |
| Earnings before Tax (EBT) 1 | -83.61 | -276.3 | -122.6 | -288.2 | -284.2 | -243.1 |
| Net income 1 | -83.61 | -276.3 | -122.6 | -288.2 | -284.2 | -243.1 |
| Net margin | - | - | -960.82% | -1,081.12% | -7,047.57% | -5,535.31% |
| EPS 2 | -0.1156 | -0.3302 | -0.1218 | -0.2897 | -0.2865 | -0.2388 |
| Free Cash Flow 1 | -28.8 | -84.04 | -214.3 | -272.9 | -209.2 | -244.6 |
| FCF margin | - | - | -1,679.78% | -1,023.64% | -5,188.36% | -5,568.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 31/10/19 | 27/04/20 | 28/04/21 | 27/04/22 | 26/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 18.8 | - | - | - | - | 213 |
| Net Cash position 1 | - | 1,154 | 818 | 314 | 65.2 | - |
| Leverage (Debt/EBITDA) | -0.3397 x | - | - | - | - | -1.013 x |
| Free Cash Flow 1 | -28.8 | -84 | -214 | -273 | -209 | -245 |
| ROE (net income / shareholders' equity) | 710% | -47.7% | -11.6% | -34.6% | -47.8% | -60.4% |
| ROA (Net income/ Total Assets) | -28.1% | -21.3% | -8.42% | -17.6% | -15.8% | -15.5% |
| Assets 1 | 297.7 | 1,297 | 1,455 | 1,637 | 1,800 | 1,572 |
| Book Value Per Share 2 | 0.0400 | 1.120 | 0.9800 | 0.6800 | 0.4900 | 0.2900 |
| Cash Flow per Share 2 | 0.0600 | 1.190 | 0.8100 | 0.5600 | 0.3300 | 0.2000 |
| Capex 1 | 2.75 | 42.3 | 76 | 198 | 113 | 103 |
| Capex / Sales | - | - | 595.26% | 743.64% | 2,796.4% | 2,352.87% |
| Announcement Date | 31/10/19 | 27/04/20 | 28/04/21 | 27/04/22 | 26/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +9.52% | 264M | |
| -3.45% | 88.14B | |
| +1.45% | 40.51B | |
| -14.43% | 31.67B | |
| +51.20% | 24.62B | |
| -14.85% | 15.65B | |
| -13.87% | 12.07B | |
| -7.87% | 11.97B | |
| -39.40% | 11.61B | |
| +5.62% | 8.81B |
- Stock Market
- Equities
- 3681 Stock
- Financials SinoMab BioScience Limited
